IS8156A - Vefjaverndandi frumuboðar til þess að vernda, endurheimta og bæta svarbúnar frumur, vefi og líffæri, og hafa lengda meðferðargetu - Google Patents

Vefjaverndandi frumuboðar til þess að vernda, endurheimta og bæta svarbúnar frumur, vefi og líffæri, og hafa lengda meðferðargetu

Info

Publication number
IS8156A
IS8156A IS8156A IS8156A IS8156A IS 8156 A IS8156 A IS 8156A IS 8156 A IS8156 A IS 8156A IS 8156 A IS8156 A IS 8156A IS 8156 A IS8156 A IS 8156A
Authority
IS
Iceland
Prior art keywords
cells
restore
organs
tissues
protect
Prior art date
Application number
IS8156A
Other languages
English (en)
Icelandic (is)
Inventor
Cerami Anthony
Brines Michael
Coleman Thomas
Original Assignee
The Kenneth S. Warren Institute, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Kenneth S. Warren Institute, Inc. filed Critical The Kenneth S. Warren Institute, Inc.
Publication of IS8156A publication Critical patent/IS8156A/is

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Virology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Psychology (AREA)
IS8156A 2003-05-19 2005-11-29 Vefjaverndandi frumuboðar til þess að vernda, endurheimta og bæta svarbúnar frumur, vefi og líffæri, og hafa lengda meðferðargetu IS8156A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47166103P 2003-05-19 2003-05-19
PCT/US2004/015733 WO2004112693A2 (en) 2003-05-19 2004-05-19 Tissue protective cytokines with an extended therapeutic window

Publications (1)

Publication Number Publication Date
IS8156A true IS8156A (is) 2005-11-29

Family

ID=33539032

Family Applications (1)

Application Number Title Priority Date Filing Date
IS8156A IS8156A (is) 2003-05-19 2005-11-29 Vefjaverndandi frumuboðar til þess að vernda, endurheimta og bæta svarbúnar frumur, vefi og líffæri, og hafa lengda meðferðargetu

Country Status (13)

Country Link
US (1) US20090258821A1 (enExample)
EP (1) EP1633305A2 (enExample)
JP (1) JP2007505159A (enExample)
KR (1) KR20060013547A (enExample)
CN (1) CN1946416A (enExample)
BR (1) BRPI0410470A (enExample)
CA (1) CA2526096A1 (enExample)
EA (1) EA200501828A1 (enExample)
IL (1) IL172035A0 (enExample)
IS (1) IS8156A (enExample)
MX (1) MXPA05012515A (enExample)
NO (1) NO20056000L (enExample)
WO (1) WO2004112693A2 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030072737A1 (en) * 2000-12-29 2003-04-17 Michael Brines Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
JP2006521405A (ja) * 2003-03-27 2006-09-21 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 発作回復におけるエリトロポイエチンの使用
US7718363B2 (en) 2003-04-25 2010-05-18 The Kenneth S. Warren Institute, Inc. Tissue protective cytokine receptor complex and assays for identifying tissue protective compounds
JP2008505184A (ja) * 2004-07-02 2008-02-21 ザ ケネス エス．ウォーレン インスティテュート，インコーポレーテッド 完全にカルバミル化されたエリトロポイエチンを生成する方法
EP1781697B1 (en) * 2004-07-07 2009-04-22 H.Lundbeck A/S Novel carbamylated epo and method for its production
US9345745B2 (en) * 2005-04-29 2016-05-24 Bo Wang Methods for treating inflammatory disorders and traumatic brain injury using stabilized non-hematopoietic EPO short peptides
US9585932B2 (en) 2005-04-29 2017-03-07 Peter C. Dowling Use of EPO-derived peptide fragments for the treatment of neurodegenerative disorders
WO2007052154A2 (en) 2005-04-29 2007-05-10 University Of Medicine And Dentistry Of New Jersey Erythropoietin-derived short peptide and its mimics as immuno/inflammatory modulators
US20070072795A1 (en) * 2005-09-28 2007-03-29 Anton Haselbeck Treatment of neurodegenerative disorders
TW201129374A (en) * 2009-10-26 2011-09-01 Lundbeck & Co As H Use of carbamylated erythropoietin for the treatment of Friedreich's ataxia
US9956265B2 (en) * 2011-04-26 2018-05-01 Ajou University Industry-Academic Cooperation Foundation Composition for aiding surgical procedures for treating ischemic vascular diseases
HRP20220519T1 (hr) * 2011-06-24 2022-05-27 Nono Inc. Kombinacijska terapija ishemije
US9241970B2 (en) 2011-12-13 2016-01-26 Nono Inc. Therapy for subarachnoid hemorrhage and ischemia
US10695402B2 (en) * 2017-03-16 2020-06-30 University Of Rochester Erythropoietin for gastrointestinal dysfunction
RU2762892C1 (ru) * 2021-02-18 2021-12-23 Федеральное государственное автономное образовательное учреждение высшего образования "Белгородский государственный национальный исследовательский университет" (НИУ "БелГУ") Способ коррекции микроциркуляторных нарушений сетчатки асиалированным эритропоэтином

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6531121B2 (en) * 2000-12-29 2003-03-11 The Kenneth S. Warren Institute, Inc. Protection and enhancement of erythropoietin-responsive cells, tissues and organs
US20030072737A1 (en) * 2000-12-29 2003-04-17 Michael Brines Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
US7300915B2 (en) * 2002-06-05 2007-11-27 The Regents Of The University Of California Use of erythropoietin and erythropoietin mimetics for the treatment of neuropathic pain
US20040091961A1 (en) * 2002-11-08 2004-05-13 Evans Glen A. Enhanced variants of erythropoietin and methods of use
JP2006521405A (ja) * 2003-03-27 2006-09-21 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 発作回復におけるエリトロポイエチンの使用

Also Published As

Publication number Publication date
MXPA05012515A (es) 2006-05-25
US20090258821A1 (en) 2009-10-15
WO2004112693A2 (en) 2004-12-29
CN1946416A (zh) 2007-04-11
IL172035A0 (en) 2009-02-11
WO2004112693A3 (en) 2006-06-29
KR20060013547A (ko) 2006-02-10
CA2526096A1 (en) 2004-12-29
JP2007505159A (ja) 2007-03-08
EA200501828A1 (ru) 2006-08-25
EP1633305A2 (en) 2006-03-15
BRPI0410470A (pt) 2006-06-20
NO20056000L (no) 2006-02-20

Similar Documents

Publication Publication Date Title
IS7619A (is) Vefjaverndandi frumuboðar til þess að vernda, endurheimta og bæta svarbúnar frumur, vefi og líffæri
PL374580A1 (en) Recombinant tissue protective cytokines and encoding nucleic acids thereof for protection, restoration, and enhancement of responsive cells, tissues, and organs
IL164079A0 (en) Methods and compositions using cellular asialodeterminants and glycoconjugates for targeting cells to tissues and organs
DK2348103T3 (da) Fremgangsmåder til anvendelse af regenerative celler til behandling af perifer karsygdom og beslægtede sygdomme
PL2399990T3 (pl) Komórki otrzymane z poporodowej pępowiny do zastosowania w leczeniu chorób serca i układu krążenia
IS6843A (is) Verndun, endurgerð og aukning á frumum, vefjum oglíffærum sem svara rauðkornavaka
WO2004009767A3 (en) Cell therapy for regeneration
DK1761266T3 (da) Forbindelser, formuleringer og fremgangsmåder til at behandle eller forebygge inflammatoriske hudsygdomme
WO2007130725A3 (en) Use of hmgb1 for protection against ischemia reperfusion injury
NO20043370L (no) N-pyrazinylfenylsulfonamider og deres anvendelse ved behandling av kemokinmedierte sykdommer
EP1581244A4 (en) NEW THERAPEUTIC TARGETS FOR CARCINOMAS
DK1513835T3 (da) Piperazinylacylpiperidinderivater, fremstilling og terapeutisk anvendelse heraf
DK1590321T3 (da) Arylalkylcarbamat-derivater, fremstilling og terapeutisk anvendelse deraf
AU2003256446A1 (en) Targeting and tracking of cells to specific organs and tissues in vivo
DK1575951T3 (da) Heterocykliske forbindelser, fremgangsmåder til fremstilling deraf og deres anvendelse i terapi
IL172035A0 (en) Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs with an extended therapeutic window
EP1551225A4 (en) KRYOKONSERVATION OF HAPEN-MODIFIED TUMOR CELLS
DK1525193T3 (da) Acylaminothiazolderivater, deres fremstilling og deres terapeutiske anvendelse
IL182263A0 (en) Cellular and genetic intervention to treat ventricular tachycardia
IS8359A (is) Vefjaverndandi frumuboðar til meðferðar og forvarnar á blóðeitrun og samloðunarmyndun
WO2007025166A3 (en) Devices, compositions and methods for the protection and repair of cells and tissues
AU2003300435A1 (en) Tissue and organ preservation, protection and resuscitation
WO2006062935A3 (en) Methods of reducing the incidence of rejection in tissue transplantation through the prophylactic use of recombinant human antihrombin
PL355298A1 (pl) Preparat dermatologiczny do leczenia uszkodzesigma skóry
IL176027A0 (en) Enoximone formulations and their use in the treatment of cardiac hypertrophy and heart failure